PROGRAM - Monday, June 4, 2012
 
Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
 
PROGRAM - MONDAY, JUNE 4, 2012
7:15AM-8:15AM
EDUCATIONAL SYMPOSIUM
INTERNATIONAL HEALTH TECHNOLOGY ASSESSMENT (HTA) TRENDS AND IMPLICATIONS FOR AN OPTIMAL HEALTH ECONOMIC RESEARCH STRATEGY (Sponsored by IMS Health) Breakfast available prior to the presentation for symposium attendees
View Symposium Description »
8:30AM-2:00PM
8:30AM- 9:00AM
WELCOME & FIRST PLENARY SESSION
 

Welcome & Presidential Address
Scott D. Ramsey, MD, PhDMark J. Sculpher MSc, PhD
2011-2012 ISPOR President and Professor of Health Economics, Centre of Health Economics, University of York, Heslington, York, UK

MEETING PROGRAM OVERVIEW
Sean Tunis, MD, MScSean R. Tunis, MD, MSc
Program Committee Chair and President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA

  ISPOR 2012 AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
Presented by: Sean D. Sullivan, PhD, RPh, Chair, ISPOR Avedis Donabedian Lifetime Achievement Award in Health Outcomes Committee & Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA
AWARDEE: Donald Patrick, PhD, MSPH, Director, University of Washington, Seattle, WA, USA
9:00AM-10:30AM
FIRST PLENARY SESSION: COMPARING THE EFFECTIVENESS OF NEW DRUGS: SHOULD THE FDA BE ASKING 'DOES IT WORK' OR 'DOES IT WORK BETTER'?
The purpose of the FDA is to assure that drugs do more good than harm for their intended uses (i.e. does it work?). Whereas, for healthcare organizations paying for drugs, "does the new drug work better than existing treatments and is any additional cost worth incurring?" are the critical questions. Regulatory and reimbursement decisions are generally made almost simultaneously, relying on a very similar body of evidence, but by different organizations. Might it improve the efficiency with which new drugs get into the market, and overall public health, if regulatory agencies more consistently considered evidence comparing the effectiveness of new drugs to available alternatives, or should they continue their current approach?
During this plenary session, the question of whether regulatory agencies should place more emphasis on evidence of comparative effectiveness will be debated.

Moderator/Speaker:
Sean R. Tunis, MD, MSc, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA
Speakers:
Mark B. McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies & Leonard D. Schaeffer Chair in Health Policy Studies, Brookings Institution, Washington, DC, USA
Vicki L. Seyfert-Margolis, PhD, Senior Advisor, Science Innovation and Policy, Office of the Chief Scientist, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, USA
10:30AM-10:45AM
10:45AM-11:45AM
ISSUE PANELS - SESSION I
10:45AM-11:45AM CLINICAL OUTCOMES RESEARCH ISSUE
IP1: WHAT HAVE WE LEARNED IN THE TRANSLATION AND DISSEMINATION OF COMPARATIVE EFFECTIVENESS RESEARCH?

Moderator: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA
Panelists: Teresa B. Gibson, PhD, Senior Director, Healthcare, Thomson Reuters, Ann Arbor, MI, USA; Justin Timbie, PhD, Associate Policy Researcher, RAND, Arlington, VA, USA; Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
10:45AM-11:45AM ECONOMIC OUTCOMES RESEARCH ISSUES
IP2: WILL CER STIMULATE OR DEPRESS INNOVATION IN HEALTH CARE?

Moderator: Sean R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy, Baltimore, MD, USA
Panelists: Darius Lakdawalla, PhD, Associate Professor, Price School of Public Policy, University of Southern California, Los Angeles, CA, USA; Sarah Garner, PhD, Associate Director, Research and Development, National Institute of Health & Clinical Excellence (NICE), London, UK; Tomas J. Philipson, PhD, Daniel Levin Professor of Public Policy Studies, Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, Chicago, IL, USA
10:45AM-11:45AM HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP3: THE COST-EFFECTIVENESS OF COST-EFFECTIVENESS ANALYSIS (CEA) IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): WHEN IS CONDUCT OF CEA IN CONJUNCTION WITH CER REQUIRED?

Moderator: J. Sanford Schwartz, MD, Leon Hess Professor of Medicine, Health Management and Economics, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Panelists: Patrick H. Conway, MD, MSCE, Chief Medical Officer & Director, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA; Mark V. Pauly, PhD, Bendheim Professor of Health Care Systems, Insurance & Economics, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA; Richard J. Willke, PhD, Senior Director & Group Lead, Global Health Economics & Outcomes Research, Pfizer, Inc., New York, NY, USA; Joe V. Selby, MD, MPH, Executive Director, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA
10:45AM-11:45AM IP4: HOW WILL FDA'S NEW DRAFT GUIDANCE ON UNSOLICITED REQUESTS FOR OFF-LABEL INFORMATION AFFECT AMCP DOSSIERS AND THE COMMUNICATION OF HEALTH ECONOMIC INFORMATION?
Moderator: Peter J. Neumann, ScD, Professor and Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Panelists: Elaine Hu Cunningham, PharmD, Senior Regulatory Review Officer, Office of Prescription Drug Promotion, U.S. Food and Drug Administration, Silver Spring, MD, USA; Sean D. Sullivan, PhD, RPh, MS, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA; Iris Tam, PharmD, Director, Managed Care Medical Communications, Genentech, Inc., South San Francisco, CA, USA
10:45AM-11:45AM IP5: SHOULD ORPHAN DRUGS BE SUBJECTED TO VALUE-BASED ASSESSMENTS?
Moderator: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Panelists: Amy K. O'Sullivan, PhD, Director, Health Economics & Outcomes Research, OptumInsight, Medford, MA, USA; Michael Barry, MD, PhD, Clinical Director, National Centre for Pharmacoeconomics, St. James's Hospital, Dublin, Ireland; Francis Pang, PhD, Senior Director, Market Access and Public Affairs, Shire Human Genetic Therapies, Inc, Route de Crassier, Switzerland
11:45AM-2:00PM
12:00PM-1:00PM
Student Research Showcase –Outcomes Research Having a High Impact on Future Health Care Decisions

This session will feature 4 outcomes research studies, conducted by ISPOR student members and presented at the ISPOR 17th Annual International Meeting, which will have a high impact on future health care decisions. A brief summary of the research study and conclusions will be presented and then the impact of the study on future health care decision(s) will be discussed.

Moderators: Karen L. Rascati, PhD, RPh, Stewart Turley/Eckerd Corporation Centennial Endowed Professor of Health Outcomes & Pharmacy Practice, University of Texas at Austin, Austin, TX, USA; Zeba M. Khan PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA; Michael L. Johnson, PhD, Associate Professor &  Director of Graduate Studies, Department of Clinical Sciences and Administration, University of Houston, Houston, TX, USA

Speakers: Laura F. Garabedian, MPH,  PhD Student in Health Policy, Harvard University, Boston, MA, USA; Mustafa Hussein, MS,  PhD student, The University of Tennessee Health Science Center, Memphis, TN, USA; Eline Picavet, BSc, PhD Student, KU Leuven, Leuven, Belgium; Rohan Mahabaleshwarkar, MS, University of Mississippi, Oxford, MS, USA

12:00PM-1:00PM
EDUCATIONAL SYMPOSIUM
DEVELOPING, USING AND VALUING A MORE REFINED EQ-5D: THE EQ-5D-5L (Sponsored by EuroQol Group) View Symposium Description »
1:00PM-2:00PM
2:00PM-4:15PM
RESEARCH POSTER PRESENTATIONS HALL CLOSED
2:00PM-3:00PM
RESEARCH PODIUM PRESENTATIONS - SESSION I
 

CANCER OUTCOMES RESEARCH

2:00PM-2:15PM

CN1

STATINS AND COLORECTAL CANCER: IS THERE A LINK?

 

Clancy ZA1, Keith SW1, Rabinowitz C1, Gagne J2, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

2:15PM-2:30PM

CN2

DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT IN BRAIN METASTASES: THE BRAIN METASTASES SYMPTOM AND IMPACT QUESTIONNIARE (BASIQ)

 

Lasch KE1, Ganguli A2, Bonthapally V2, Pompilus F1, Delbecque L1, Fitzgerald K1, Ray S2
1Adelphi Values, Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA

2:30PM-2:45PM

CN3

MULTI-LEVEL MODELING OF OVERALL MORTALITY FOR MEN DIAGNOSED WITH PROSTATE CANCER IN FLORIDA

 

Xiao H1, Tan F2, Gwede C3, Huang Y4, Goovaerts P5, Adunlin G1, Ali A1
1Florida A&M University, Tallahassee, FL, USA, 2Indiana University-Purdue University, Indianapolis, IN, USA, 3Moffitt Cancer Center, Tampa, FL, USA, 4Florida Department of Health, Tallahassee, FL, USA, 5BioMedware, Inc, Ann Arbor, MI, USA

2:45PM-3:00PM

CN4

TOTAL HEALTH CARE COSTS FOR COLORECTAL CANCER PATIENTS FOLLOWING METASTATIC DIAGNOSIS

 

Chastek B1, Kulakodlu M1, Valluri S2, Seal B2
1OptumInsight, Eden Prairie, MN, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA

  NEW CONCEPTS FOR HEALTH CARE DECISION-MAKING
2:00PM-2:15PM

CO1

INDIVIDUAL DECISIONS AND SOCIAL VALUE: A CONCEPTUAL FRAMEWORK TO EXPLORE ALTERNATIVE DECISION MAKING APPROACHES AND THE VALUE OF HETEROGENEITY IN THE ERA OF INDIVIDUALIZED CARE

 

Espinoza MA, Manca A, Sculpher MJ, Claxton K
University of York, Heslington, York, UK

2:15PM-2:30PM

CO2

ADVANCING THE METHODS OF COST-EFFECTIVENESS ANALYSIS: WHY IT'S TIME TO MOVE ON FROM ICERS AND THRESHOLDS

 

Paulden M
University of Toronto, Toronto, ON, Canada

2:30PM-2:45PM

CO3

MINIMIZING THE COSTS OF ANALYZING THE VALUE OF HEALTH RESEARCH

 

Hoomans T, Seidenfeld J, Meltzer D
University of Chicago, Chicago, IL, USA

2:45PM-3:00PM

CO4

COST-EFFECTIVENESS ANALYSIS - APPROPRIATE FOR ALL SITUATIONS?

 

Standaert B1, Ethgen O2, Emerson RA3
1GlaxoSmithKline Biologicals, Wavre, Belgium, 2University of Liege, Liege, Belgium, 3Emerson Consulting, Tervuren, Belgium

  MEDICARE POLICIES & HEALTH CARE
2:00PM-2:15PM

ME1

EFFECT OF MEDICARE PART D ON DRUG UTILIZATION, DRUG EXPENDITURES, AND HEALTH CARE SPENDING IN PATIENTS WITH CHRONIC PULMONARY OBSTRUCTIVE DISEASE

 

Cheng LI, Rascati KL
The University of Texas at Austin, Austin, TX, USA

2:15PM-2:30PM

ME2

EFFECT OF MEDICARE PRESCRIPTION DRUG PROGRAM (PART D) ON MEDICATION ADHERENCE FOR DUAL ELIGIBLES: CASE OF ACEIS AND ARBS

 

Kim JA, Park T
University of Minnesota, Minneapolis, MN, USA

2:30PM-2:45PM

ME3

A POLICY EVALUATION OF INSTITUTING PATIENT NAVIGATION PROGRAM IN MEDICARE: DOES IT WORK FOR LUNG CANCER PATIENTS

 

Shih YCT1, Chien CR2, Moguel MR3, Hernandez M3, Hajek R3, Jones L3
1The University of Chicago, Chicago, IL, USA, 2China Medical University Hospital, Taichung, Taiwan, 3University of Texas MD Anderson Cancer Center, Houston, TX, USA

2:45PM-3:00PM

ME4

PERIOPERATIVE OUTCOMES, COMPLICATIONS, AND COSTS ASSOCIATED WITH LUMBAR SPINAL FUSION IN OLDER PATIENTS WITH SPINAL STENOSIS AND SPONDYLOLISTHESIS: ANALYSIS OF THE UNITED STATES MEDICARE CLAIMS DATABASE

 

Auerbach JD1, Ong KL2, Lau E3, Ochoa J4, Schmier JK5, Zigler JD6
1Bronx-Lebanon Hospital Center, Bronx, NY, USA, 2Exponent, Inc., Philadelphia, PA, USA, 3Exponent, Inc., Menlo Park, CA, USA, 4Exponent, Inc., Bellevue, WA, USA, 5Exponent, Inc., Alexandria, VA, USA, 6Musculoskeletal Clinical Regulatory Advisers, LLC, Washington, DC, USA

  HEALTH CARE RISK MANAGEMENT
2:00PM-2:15PM

RM1

REAL-WORLD EVIDENCE ON THE EFFECTS OF STATIN-FIBRATE COMBINATION THERAPY IN TYPE-2 DIABETES: THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) TRIAL REDUX

 

Borah BJ, Shah N, Reinalda M, Montori V
Mayo Clinic, Rochester, MN, USA

2:15PM-2:30PM

RM2

DEVELOPMENT OF A PULMONARY EXACERBATION RISK SCORE AMONG CF PATIENTS NOT RECEIVING RECOMMENDED THERAPIES FOR PULMONARY CARE

 

Sawicki G1, Ayyagari R2, Zhang J3, Signorovitch J2, Fan L2, Latremouille-Viau D2, Shi L4
1Children's Hospital Boston, Boston, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Tulane University, New Orleans, LA, USA

2:30PM-2:45PM

RM3

ANTIPSYCHOTIC USE AND RISK OF ALL-CAUSE MORTALITY IN ELDERLY DUAL ELIGIBLE BENEFICIARIES

 

Aparasu RR, Chatterjee S, Mehta S, Chen H
University of Houston, Houston, TX, USA

2:45PM-3:00PM

RM4

A SYSTEMATIC REVIEW OF COSTS ASSOCIATED WITH PRESCRIPTION OPIOID RISKS

 

Cangelosi MJ, Saunders T, Neumann PJ, Cohen JT
Tufts Medical Center, Boston, MA, USA

  IMPORTANCE OF SELECTION BIAS IN HEALTH CARE RESEARCH
2:00PM-2:15PM

SB1

COMPARISON OF MEDICAL CARE CONSUMPTION BETWEEN DULOXETINE INITIATORS AND PREGABALIN INITIATORS AMONG FIBROMYALGIA PATIENTS

 

Sun P1, Peng X2, Sun S3, Novick D4, Faries D2, Andrews JS2, Wohlreich M2, Wu A5
1Kailo Research Group, Fishers, IN, USA, 2Eli Lilly and Company, Inc., Indianapolis, IN, USA, 3Kailo Research Group, Fremont, CA, USA, 4Eli Lilly and Company, Inc., Windlesham, Surrey, UK, 5Kailo Research Group, Los Angeles, CA, USA

2:15PM-2:30PM

SB2

COMPARATIVE EFFECTIVENESS OF ON-PUMP AND OFF-PUMP CORONARY ARTERY BYPASS GRAFTING AMONG ELDERLY PATIENTS – A RETROSPECTIVE ANALYSIS OF MEDICARE CLAIMS DATA

 

Datar M, Yang Y, Mahabaleshwarkar R, Bentley JP, Banahan BF
University of Mississippi, University, MS, USA

2:30PM-2:45PM

SB3

INCREMENTAL CLINICAL AND ECONOMIC BURDEN OF UNCONTROLLED PARTIAL-ONSET SEIZURES IN A PRIVATELY-INSURED POPULATION

 

Paradis PE1, Parisé H1, Duh MS2, Bowers BW3, Faught E4
1Groupe d'analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA, 4Emory University, Atlanta, GA, USA

2:45PM-3:00PM

SB4

PROPENSITY-SCORE MATCHING (PSM) TO CONTROL FOR SELECTION BIAS IN “REAL-WORLD” TREATMENT COMPARISONS: A CAUTIONARY TALE CONCERNING ANTIBIOTIC THERAPY FOR INFECTIOUS DISEASE

 

Berger A1, McKinnon PS2, Larson K2, Crompton M2, Hennegan K1, Weber DJ3, Boening AJ2, Oster G1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Cubist Pharmaceuticals, Inc., Lexington, MA, USA, 3University of North Carolina School of Medicine, Chapel Hill, NC, USA

3:15PM-4:15PM
RESEARCH PODIUM PRESENTATIONS - SESSION II
 

COMPARATIVE EFFECTIVENESS RESEARCH & HEALTH CARE

3:15PM-3:30PM

CE1

COST EFFECTIVENESS TRENDS OF HIGH BUDGET IMPACT DRUGS (2006-2012)

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

3:30PM-3:45PM

CE2

COMPARATIVE EFFECTIVENESS OF MONOTHERAPY WITH MOOD STABILIZERS VERSUS ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS: A RETROSPECTIVE CLAIMS-DATA STUDY

 

Mehta S1, Patel A2, Aparasu RR2, Perez MO3, Chen H2
1Pharmerit North America, LLC., Bethesda, MD, USA, 2University of Houston, Houston, TX, USA, 3Legacy Community Health Services, Houston, TX, USA

3:45PM-4:00PM

CE3

GRACE CHECKLIST: RATING THE STRENGTH OF EVIDENCE FOR OBSERVATIONAL STUDIES OF COMPARATIVE EFFECTIVENESS

 

Dreyer N1, Velentgas P1, Duddy A1, Westrich KD2, Dubois RW2
1Outcome, A Quintiles Company, Cambridge, MA, USA, 2National Pharmaceutical Council, Washington, DC, USA

4:00PM-4:15PM

CE4

A FRAMEWORK FOR STAKEHOLDER ENGAGEMENT IN COMPARATIVE EFFECTIVENESS RESEARCH

 

Lavallee DM1, Desai PJ1, Mullins CD2, Deverka PA1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

  CARDIOVASCULAR DISORDERS OUTCOMES RESEARCH
3:15PM-3:30PM

CV1

DIFFERENCES IN PROCESSES AND OUTCOMES OF CARE IN ELDERLY HYPERTENSIVE DIABETIC PATIENTS WITH AND WITHOUT DEMENTIA

 

Chitnis AS, Johnson ML
University of Houston, Houston, TX, USA

3:30PM-3:45PM

CV2

THE HIDDEN BURDEN OF PRESCRIPTION COST CUTTING IN A DIAGNOSED ATRIAL FIBRILLATION POPULATION IN THE UNITED STATES

 

Gupta S1, Gross H1, DiBonaventura M2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

3:45PM-4:00PM

CV3

COMPARATIVE EFFECTIVENESS OF STATINS IN A LARGE MANAGED CARE ORGANIZATION: CARDIOVASCULAR EVENT RATE AND TOTAL HEALTH CARE COST

 

Wang JJ1, White TJ2, Fisher VS3, DeVries A4, McNeeley B4, Abarca J5
1WellPoint, Inc., Thousand Oaks, CA, USA, 2WellPoint, Inc., Costa Mesa, CA, USA, 3WellPoint, Inc., Southern Pines, NC, USA, 4HealthCore, Inc., Wilmington, DE, USA, 5WellPoint, Inc., Indianapolis, IN, USA

4:00PM-4:15PM

CV4

GRACE RISK PREDICTION INDEX, CHARLSON COMORBIDITY INDEX, OR BOTH, TO PREDICT OUTCOMES ASSOCIATED WITH ACUTE CORONARY SYNDROME

 

Erickson S1, Eagle KA1, Kline-Rogers E2
1University of Michigan, Ann Arbor, MI, USA, 2University of Michigan Health System, Ann Arbor, MI, USA

  EFFECT OF DRUG POLICIES ON HEALTH CARE
3:15PM-3:30PM

DR1

PUBLIC HEALTH INNOVATION: BIOPHARMACEUTICALS LOST IN TRANSLATION?

 

Halim N, Doyle J
Quintiles Global Consulting, Hawthorne, NY, USA

3:30PM-3:45PM

DR2

THE RELATIONSHIP BETWEEN PSEUDOEPHEDRINE SALES AND CLANDESTINE METHAMPHETAMINE LABS

 

Talbert J, Blumenschein K, Freeman PR
University of Kentucky, Lexington, KY, USA

3:45PM-4:00PM

DR3

ESTABLISHMENT OF AN INNOVATIVE COLLABORATIVE BETWEEN THE DRUG SAFETY AND EFFECTIVENESS NETWORK IN CANADA AND ISPOR FOR APPLICATION AND DEVELOPMENT OF NETWORK META-ANALYSIS

 

Lee K1, Shukla V1, Coyle D2, Wells G3
1Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3University of Ottawa Heart Institute, Ottawa, ON, Canada

4:00PM-4:15PM

DR4

CLARITY, CONSISTENCY AND TRANSPARENCY IN DECISION-MAKING: TESTING A NOVEL P&T FRAMEWORK FOR ASSESSING EVIDENCE

 

Graff J1, Dean B2, Ko K2, Localio AR3, Dubois RW1
1National Pharmaceutical Council, Washington , DC, USA, 2Cerner Corporation, Beverly Hills, CA, USA, 3University of Pennsylvania School of Medicine, Philadelphia, PA, USA

  MEDICATION ADHERENCE & HEALTH CARE
3:15PM-3:30PM

MA1

MEDICATION ADHERENCE AND PERSISTENCE OF PRASUGREL INITIATORS POST ACS-PCI

 

Simeone JC1, Nordstrom B1, Zhao Z2, Molife C2, McCollam PL2, Ye X3, Effron MB2
1United BioSource Corporation, Lexington, MA, USA, 2Eli Lilly and Company, Inc., Indianapolis, IN, USA, 3Daiichi Sankyo, Inc, Parsippany, NJ, USA

3:30PM-3:45PM

MA2

COMPARISON OF HEALTH CARE COSTS FOR CROHN'S DISEASE PATIENTS WHO ARE ADHERENT VERSUS INTERMITTENTLY ADHERENT WITH INFLIXIMAB THERAPY

 

Feagan B1, Kozma C2, Slaton T3, Olson W4, Wan G5
1Robarts Research Institute The University of Western Ontario, London, ON, Canada, 2Independent Research Consultant/ University of South Carolina, St. Helena Island, SC, USA, 3Independent Consultant, West Columbia, SC, USA, 4Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 5Janssen Scientific Affairs, LLC, Horsham, PA, USA

3:45PM-4:00PM

MA3

COMPARATIVE OUTCOMES OF FIBROMYALGIA PATIENTS WHO INITIATED DULOXETINE OR PREGABALIN: MEDICATION ADHERENCE AND DIRECT MEDICAL COSTS

 

Sun P1, Peng X2, Sun S3, Novick D4, Faries D2, Andrews J2, Wu A5, Wohlreich M2
1Kailo Research Group, Fishers, IN, USA, 2Eli Lilly and Company, Inc., Indianapolis, IN, USA, 3Kailo Research Group, Fremont, CA, USA, 4Eli Lilly and Company, Inc., Windlesham, Surrey, UK, 5Kailo Research Group, Los Angeles, CA, USA

4:00PM-4:15PM

MA4

DOES PEN HELP WHEN ELDERLY PATIENTS WITH TYPE-2 DIABETES INITIATE INSULIN? A REAL-WORLD RETROSPECTIVE STUDY OF INITIATING INSULIN GLARGINE VIA DISPOSABLE PEN VERSUS VIAL

 

Miao R1, Wei W1, Xie L2, Baser O2
1Sanofi-Aventis, Bridgewater, NJ, USA, 2STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

  OUTCOMES RESEARCH STUDIES USING MODELING
3:15PM-3:30PM

MO1

NEW CONCEPTS IN DISCRETE CHOICE PREFERENCE MEASUREMENT: AN APPLICATION TO DRUG TREATMENT FOR JUVENILE IDIOPATHIC ARTHRITIS

 

Regier DA1, Burnett HF2, Ungar W2
1BC Cancer Agency Research Centre, Vancouver, BC, Canada, 2Hospital for Sick Children, Toronto, ON, Canada

3:30PM-3:45PM

MO2

THE COST-EFFECTIVENESS OF PRIMARY STROKE CENTERS FOR ACUTE STROKE CARE

 

Guzauskas GF1, Boudreau DM2, Villa KF3, Levine SR4, Veenstra DL5
1University of Washington, Seattle, WA, USA, 2Group Health Research Institute, Seattle, WA, USA, 3Genentech, Inc., South San Francisco, CA, USA, 4SUNY Downstate Medical Center, Brooklyn, NY, USA, 5University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

3:45PM-4:00PM

MO3

COST-EFFECTIVENESS ANALYSIS OF DIFFERENT STRATEGIES FOR FRAGILITY FRACTURE PREVENTION IN UNITED STATES MALE VETERANS

 

Lafleur J1, Nelson RE2, Adler RA3, Nebeker JR2, Nelson S2, Smith J4, Malone DC5
1University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, UT, USA, 2University of Utah, Salt Lake City, UT, USA, 3Virginia Commonwealth University, Richmond, VA, USA, 4VA Salt Lake City Healthcare System, Salt Lake City, UT, USA, 5University of Arizona, Tucson, AZ, USA

4:00PM-4:15PM

MO4

ECONOMIC EVALUATION OF TREATMENT STRATEGIES FOR LATE-PRESENTATION ACUTE ISCHEMIC STROKE

 

Nam J, O'Reilly D
PATH Research Institute, McMaster University, Hamilton, ON, Canada

4:15PM-4:45PM
BREAK & EXHIBITS VIEWING
4:30PM-8:30PM
4:45PM-5:45PM
WORKSHOPS - SESSION I
4:45PM-5:45PM Economic Outcomes Research
W1: FUNDAMENTALS OF MODEL CALIBRATION: THEORY & PRACTICE

Discussion Leaders: Douglas Taylor, MBA, Associate Director, Health Economics & Outcomes Research, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA; Ankur Pandya, MPH, Graduate Student, School of Public Health, Harvard University, Boston, MA, USA; David Thompson, PhD, Senior Vice President, Health Economics & Outcomes Research, OptumInsight, Medford, MA, USA
4:45PM-5:45PM HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W2: ELICITING PATIENT-CENTERED OUTCOMES: DETERMINING THE RELATIVE STRENGTHS, OPPORTUNITIES AND CHALLENGES OF 5 COMMON RESEARCH DESIGNS

Discussion Leaders: Bryan R. Luce, PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Lori Frank, PhD, Research Scientist, Patient Centered Outcomes Research Institute, Washington, DC, USA; Karin S. Coyne, PhD, MPH, Senior Research Leader, Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; Kathleen W. Wyrwich, PhD, Senior Research Leader, United BioSource Corporation, Bethesda, MD, USA
4:45PM-5:45PM W3: REWARDING INNOVATION IN THE UNITED STATES AND EUROPE: WHAT'S THE BEST WAY FORWARD?
Discussion Leaders: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Alistair Mcguire, PhD, Head of Social Policy, Health and Social Care, London School of Economics, London, UK; Linus Jonsson, PhD, MD, MSc, Vice President, Health Economics & Outcomes Research, OptumInsight, Stockholm, Sweden; Monique Martin, MBA, MSc, Vice President, UK Operations, OptumInsight, Uxbridge, Middlesex, UK
4:45PM-5:45PM W4: ASSESSING THE VALUE OF PERSONALISED MEDICINE (PM) IN PRACTICE – UTILISATION, ECONOMICS AND PREFERENCES
Discussion Leaders: Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and  Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; Kathryn Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA; Nathalie A. Kulin, MSc, Research Analyst, Community Health Sciences, University of Calgary, Calgary, AB, Canada; Ilia L Ferrusi, BSc, PhD Candidate, Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada
4:45PM-5:45PM PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH
W5: UTILIZATION OF RASCH MEASUREMENT MODELS FOR ASSESSING VALIDITY: A MIXED METHODS APPROACH

Discussion Leaders: Stacie Hudgens, MA, Vice President, Evidence Generation, Analysis, and Interpretation & Global Practice Lead, Statistics and Psychometrics, Adelphi Values, Boston, MA, USA; Denise Globe, PhD, Senior Director, Global Health Outcomes Strategy and Research, Allergan, Inc., Irvine, CA, USA; Somali Misra Burgess, PhD, Vice President and Director, Patient Reported Outcomes, Adelphi Values, Boston, MA, USA
4:45PM-5:45PM USE OF REAL WORLD DATA
W6: DISTRIBUTED SEQUENTIAL COHORT ANALYSES FOR RAPID EVIDENCE GENERATION IN THE EARLY MARKETING PERIOD

Discussion Leaders: Joshua Gagne, PharmD, ScD, Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Sebastian Schneeweiss, MD, ScD, Associate Professor of Medicine and Epidemiology & Vice Chief, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Jeremy A. Rassen, ScD, Assistant Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Jens Grueger, PhD, Vice President & Head, Global Health Economics & Pricing, F. Hoffmann-LaRoche Ltd, Basel, Switzerland
4:45PM-5:45PM W7: SAMPLE SIZE ESTIMATION FOR OBSERVATIONAL STUDIES
Discussion Leaders: Terry Alan Cox, MD, PhD, Director, Late Phase Analysis & Reporting, Quintiles, Inc., Rockville, MD, USA; Eric Gemmen, MA, Senior Director, Scientific Affairs, Real World & Late Phase Research, Quintiles, Inc., Rockville, MD, USA; Zhaohui Su, PhD, Director, Biostatistics, Outcome Sciences, a Quintiles Company, Cambridge, MA, USA; Ari Marcus, MPH, Associate Director, Biostatistics, Outcome Sciences, a Quintiles Company, Cambridge, MA, USA
6:00PM-7:00PM
ISPOR FORUMS - SESSION I
6:00PM-7:00PM ASSESSING NETWORK META ANALYSIS STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing network meta analysis studies for health care decision makers will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI). The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force

Moderator & Speaker: Jeroen Jansen, PhD, Chair, CER-CI Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force and Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA

Speakers: Jessica Daw, PharmD, MBA, Director, Clinical Pharmacy UPMC Health Plan, Pittsburgh, PA, USA
6:00PM-7:00PM MIXING MODES OF PATIENT-REPORTED OUTCOMES DATA COLLECTION IN CLINICAL TRIALS: RECOMMENDATIONS
Mixing modes of data collection in clinical trials involves the potential for increased measurement error which may impact the treatment effect. Speakers will discuss recommended steps to support the decision to mix modes including selecting the appropriate mode, performing a faithful migration, and evaluating measurement equivalence between modes, as well as operational and statistical considerations for registration trials using PROs in support of medical product label claims. Presented by the ISPOR PRO Mixed Modes Task Force

Moderator & Speaker: Sonya Eremenco, MA, Chair, ISPOR PRO Mixed Modes of Data Collection Task Force and ePRO Manager, United BioSource Corporation, Bethesda, MD, USA 

Speakers:
Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA; Jean Paty, PhD, Chief Scientist and Regulatory Officer, invivodata, inc., Pittsburgh, PA, USA
6:00PM-7:00PM ASSESSING PROSPECTIVE OBSERVATIONAL STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing prospective observational studies for health care decision makers will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI). The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Interpreting Prospective Observational Studies for Health Care Decision Makers Task Force

Moderator & Speaker: Marc Berger, MD, Chair, CER-CI Interpreting Prospective Observational Studies for Health Care Decisions Task Force and Executive Vice President & Senior Scientist, OPTUMInsight, New York, NY, USA

Speakers:
C. Daniel Mullins, PhD, Professor, University of Maryland School of Pharmacy, Pharmaceutical Health Services Research, Baltimore, MD, USA; John Graham, PharmD, Group Director, Health Services, US Medical, Bristol-Myers Squibb, Princeton, NJ, USA; Scott Devine, MPH, PhD, Outcomes Research Scientist, US Outcomes Research, Merck & Co, Inc., St. Louis, MO, USA
6:00PM-7:00PM ASSESSING MODELING STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool” for assessing modeling studies for health care decision makers will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI). The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Interpreting Modeling Studies for Health Care Decision Makers Task Force

Moderator: Cheryl Kaltz, RPh, MBA, Lead Clinical Pharmacist, The University of Michigan Prescription Drug Plan, University of Michigan, Ann Arbor, MI, USA.

Speakers: David Eddy, MD, PhD, Chair, CER-CI Interpreting Modeling Studies for Health Care Decisions Task Force and Founder & Medical Director, Archimedes Inc., San Francisco, CA, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University and Senior Vice-President, Research, United BioSource Corporation, Lexington, MA, USA
6:00PM-7:00PM ISPOR HEALTH ECONOMIC EVALUATION PUBLICATION GUIDELINES - CHEERS: GOOD REPORTING PRACTICES
Task Force findings on the necessary structure and content to effectively report health economic evaluation studies will be presented.  A draft checklist, ISPOR Consolidated Health Economic Evaluation Reporting Standards (CHEERS), intended to be a practical tool to help authors, editors, and peer-reviewers produce reports that convey details of a study transparently and consistently, will be reviewed. Presented by the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS Task Force

Moderator & Speaker: Don Husereau, BScPharm, MSc, Chair, ISPOR Health Economic Evaluation Publication Guidelines Task Force, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

Speakers:
Chris Carswell, MSc, Editor, Pharmacoeconomics, Auckland, New Zealand; Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Josephine Mauskopf, PhD, Former Editor-in-Chief, Value in Health and Vice President of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
6:00PM-7:00PM PATIENT PROTECTION AND AFFORDABLE CARE ACT: HOW THE OBAMA HEALTH CARE LAW WILL AFFECT FUTURE GENERATIONS
This forum will discuss how the Patient Protection and Affordable Care Act will affect pharmacists, consumers, physicians and health care providers in the upcoming years.  Speakers will also review pros and cons of the Act and whether it will be used by other countries as a template for health care. Presented by the ISPOR Student Council

Moderators: Zeba M. Khan, RPh, PhD, Advisor, ISPOR Student Network and Vice President, Pricing and Market Access, Celgene Corporation, Summit, NJ, USA;  Abhishek S. Chitnis, M.Pharm, MS, Chair 2011-2012, ISPOR Student Network and Doctoral Candidate, Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX, USA

Speakers: Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and  Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; Ansgar Hebborn, PhD, Global Head, Economic Value Strategy, F. Hoffman-La Roche, Basel, Switzerland; Rachael Fleurence, PhD, Director, Oxford Outcomes, Bethesda, MD, USA
6:00PM-7:00PM PROS & CONS OF PRICING AND REIMBURSEMENT SYSTEMS IN SAUDI ARABIA, EGYPT, UNITED ARAB EMIRATES, QATAR AND JORDAN
Evaluation of pricing and reimbursement systems is desirable in an increasingly cost-sensitive environment. This forum will identify steps in the decision-making and approval process for pharmaceutical pricing and reimbursement. Speakers from the Arabic-speaking countries will describe organizations that play an important role in health care decisions and will provide data requirements needed to support these decisions. Future perspectives for better pricing and reimbursement will be presented.  The establishment of a pharmacoeconomics unit and the conduct of budget impact analysis, in order to provide evidence for the value of drugs in delivering expected outcomes for patients by evaluating the clinical and economic effectiveness of pharmaceuticals, will be discussed. Presented by the ISPOR Arabic Network

Moderator: Ibrahim Alabbadi, PhD, MBA, President, ISPOR Jordan Regional Chapter, Associate Professor of Pharmacoeconomics & Pharmaceutical Marketing, Faculty of Pharmacy and Deputy General Manager, Administrative Affairs, Jordan University Hospital, University of Jordan, Amman, Jordan

Speakers: Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Regional Chapter and Director, Drug Policy & Economics Center, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia; Mahmoud Elmahdawy, PharmD, President, ISPOR Egypt Regional Chapter and Director, Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Egyptian Ministry of Health, Cairo, Egypt; Ola Ghaleb Ahmed Al Ahdab, PhD, President, ISPOR United Arab Emirates Regional Chapter, Pharmaceutical Advisor, Drug Registration Department, Ministry of Health and Assistant Professor of Pharmacy Practice, College of Pharmacy, Sharjah University and Ajman University of Science and Technology, Abu Dhabi, United Arab Emirates; Daoud Al-Badriyeh, PhD, Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar
7:00PM-7:30PM
ISPOR ANNUAL BUSINESS MEETING
 

Call to order:
Mark J. Sculpher, MSc, PhD,
2011-2012 ISPOR President
Executive Director’s Report:
Marilyn Dix Smith, RPh, PhD,
ISPOR Executive Director
Treasurer’s Report:
Karen Rascati, RPh,PhD,
ISPOR Treasurer
Audit Report:
Newell McElwee, PharmD, MSPH

Value in Health Co-Editor’s –in-Chief Report:
C. Daniel Mullins, PhD
and Michael Drummond, PhD
Value in Health Regional Issues Co-Editor’s-in-Chief Report:
Bong-min Yang, PhD
and Federico Augustovski, MD, MSc, PhD
ISPOR CONNECTIONS Editor-in-Chief Report:
David Thompson, PhD

Member Open Discussion:
ISPOR Members

New Business:
Mark J. Sculpher, MSc, PhD

7:00PM-8:00PM
ISPOR FORUM
7:00PM-8:00PM SUPPLY OF PHARMACEUTICAL DRUGS IN RUSSIA: PRESENT AND FUTURE
This forum will focus on issues relating to the supply of pharmaceutical drugs in Russia and potential solutions.  Issues such as the purchasing of unregulated “generic” medicines of unknown quality, drug price controls leading to drug shortages, drug insurance myths, and update on orphan drugs will be discussed.  Presented by the ISPOR Russia Regional Chapter.

Moderator: Pavel Vorobiev, MD, PhD, MSc, President, ISPOR Russia Regional Chapter and Professor, Faculty of Postgraduate Education & Head, Research Department on Health Care  Standardization Problems, Sechenov Moscow Medical Academy, Moscow, Russia

Speakers: Olga V. Pribitkova, PhD, Visiting Chief Clinical Pharmacologist, Health Care Department, Chelyabinsk, Russia; Alexandr K. Khadjidis, MD, Chief Clinical Pharmacologist and President of St. Petersburg Clinical Pharmacologists’ Medical Professional Association, Moscow, Russia
7:00PM-8:00PM
7:00PM-8:30PM

Professor Donald Patrick, PhD, MSPH

Professor Donald Patrick, PhD, MSPH, has worked on outcomes for over 45 years. He is Professor of Health Services at the University of Washington with appointments in Epidemiology, Pharmacy, Rehabilitation Medicine, and Sociology and is a Full Member of the Fred Hutchinson Cancer Research Center. Dr. Patrick is internationally recognized as a leading developer and user of multiple generic and disease-specific measures; he directs the Seattle Quality of Life Group (www.seaqolgroup.org) and works on projects funded by the National Institutes of Health, AHRQ, and Industry. Dr. Patrick is active in research on service systems, health disparities in cancer populations, children and adolescents, and people with disabilities. Dr. Patrick is a member of the Institute of Medicine, and as a Special Government Employee, he contributed to the FDA Guidance on Patient-Reported Outcome Measures for Use in Medical Product Development and Labeling Claims. Dr. Patrick is a member of the Board of Directors of ISPOR and participates actively in Task Forces and other work. He is author of numerous articles and monographs, a classic book written with Pennifer Erickson entitled, Health Status and Health Policy and a book with Richard Deyo entitled, Hope or Hype: The Obsession with Medical Advance and the High Cost of False Promises.





Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.